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Abstract
Background: Insect baculovirus-produced Human immunodeficiency virus type 1 (HIV-1) Gag virus-like-particles
(VLPs) stimulate good humoral and cell-mediated immune responses in animals and are thought to be suitable as
a vaccine candidate. Drawbacks to this production system include contamination of VLP preparations with
baculovirus and the necessity for routine maintenance of infectious baculovirus stock. We used piggyBac
transposition as a novel method to create transgenic insect cell lines for continuous VLP production as an
alternative to the baculovirus system.
Results: Transgenic cell lines maintained stable gag transgene integration and expression up to 100 cell passages,
and although the level of VLPs produced was low compared to baculovirus-produced VLPs, they appeared similar
in size and morphology to baculovirus-expressed VLPs. In a murine immunogenicity study, whereas baculovirus-
produced VLPs elicited good CD4 immune responses in mice when used to boost a prime with a DNA vaccine, no
boost response was elicited by transgenically produced VLPs.
Conclusion: Transgenic insect cells are stable and can produce HIV Pr55 Gag VLPs for over 100 passages: this
novel result may simplify strategies aimed at making protein subunit vaccines for HIV. Immunogenicity of the Gag
VLPs in mice was less than that of baculovirus-produced VLPs, which may be due to lack of baculovirus
glycoprotein incorporation in the transgenic cell VLPs. Improved yield and immunogenicity of transgenic cell-
produced VLPs may be achieved with the addition of further genetic elements into the piggyBac integron.
Background
Human immunodeficiency virus type 1 (HIV-1) is
responsible for the current infection of over 20 million
people and the death of over 2 million living in sub-
Saharan Africa [1]. Subtype C infections predominate in
southern Africa and represent a large portion of the
world wide infections [1], highlighting the need to
develop a safe and effective vaccine based on Subtype C.
The HIV-1 precursor structural protein Pr55 Gag has
been targeted as a potential candidate in vaccine studies as
it is able to self-assemble and bud from a variety of cell
systems to form non-replicating and non-infectious virus-
like particles (VLPs) with good humoral and cell-mediated
immune responses in animals. To date, Gag VLPs have
been generated using various eukaryotic expression sys-
tems, but most often via the baculovirus-based transient
protein expression system in insect cell cultures [2,3]. We
have shown that baculovirus-derived HIV-1 Pr55 subtype
C VLPs are able to elicit strong cellular immune responses
in mice and baboons when administered as a boost to a
HIV-1 gag DNA vaccine prime [4,5].
However, there are significant potential drawbacks to
use of the baculovirus expression system: these include
the necessity for constant maintenance of baculovirus
stocks, the need for fresh batch infections to be made
each time the product is required, and co-purification of
recombinant baculovirus or baculovirus proteins with
VLPs. The creation of a transgenic cell line for continu-
ous culture and protein production may provide a way
to bypass production issues arising with the use of
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baculovirus particle contamination of VLP preparations.
The only reported attempts to transform Spodoptera
frugiperda insect cells in culture include the random
integration of an entire expression plasmid into the insect
genome through recombination under antibiotic selec-
tion [6-11]. Transposon mutagenesis is an ideal alterna-
tive as it is based on a naturally occurring system in
insect cells and has been extensively used to transpose
many insect species [12,13]. The piggyBac transposable
element has been widely studied and is favoured as a use-
ful tool in insect transgenesis due to its simplicity of
movement and often high frequency of transformation
[14]. This class II element is derived from the cabbage
looper moth Trichoplusia ni and is a member of the
TTAA-target site-specific class of transposable elements
[15]. It exclusively targets TTAA sites and duplicates this
site upon insertion. The element is 2476 bp in length and
encodes a single open reading frame (1.8 kbp) and termi-
nates with 13 bp inverted terminal repeats (ITR). The
ORF encodes a putative transposase (molecular weight of
64 kDa) which is responsible for the movement of the
element [13]. Transgene integration into an insect gen-
ome is made possible by replacing the transposase ORF
in the piggyBac vector with the transgene, while supply-
ing the transposase in trans [13,15].
A number of whole insects from species spanning
three orders [13,16] as well as non-insect species ran-
ging from planarian to mammalian cells [17-20] have
been transformed using the piggyBac vector system.
This wide range of utility for this element makes it an
attractive genetic tool. piggyBac transposons are favored
over other elements as they are able to transpose large
DNA fragments (9.6-14 kb) [20] making them suitable
for applications in dual expression vectors designed to
include selection markers, transcriptional activators or
immune enhancer elements. Many pest species do not
have transposons closely related to this element and the
chance of re-transposition has been shown to be very
low in several insect species studied [18,21-23].
No studies involving piggyBac transposon-mediated
mutagenesis of cultured Spodoptera insect cell lines have
been reported to date. Here we report the creation of
transgenic Spodoptera frugiperda cell lines using the pig-
gyBac system to express HIV-1 Gag protein, with the aim
of developing a system for continuous production of
HIV-1 Gag VLPs for vaccine studies. The immunogeni-
city of these transgenically expressed VLPs is compared
to that of baculovirus produced VLPs in BALB/c mice.
Methods
Cell lines
The Spodoptera frugiperda-derived Sf21 cell line (Invi-
trogen) was maintained as a monolayer at 27°C in TC-
100 insect medium (Sigma) supplemented with 10%
(v/v) foetal bovine serum (FBS), 50 μg/ml neomycin,
69.2 μg/ml penicillin G and 100 μg/ml streptomycin.
The Spodoptera frugiperda-derived Sf9 cell line (Invitro-
gen) was maintained as a shaking culture at 27°C,
140 rpm in SF900 II SFM media (Gibco) supplemented
with 10 μg/ml gentamicin. The High 5™ cell line is
derived from Trichoplusia ni (Invitrogen) and was main-
tained as a shaking culture in Express Five® SFM media
(Gibco) supplemented with 10 ug/ml gentamicin and
18 mM glutamine.
Baculovirus produced Gag VLPs
The human codon-optimised HIV-1 subtype C gag
DNA sequence used in this study was derived from the
DNA vaccine plasmid pTHgagC [24,25]. The gag
sequence used encodes a myristoylation signal respon-
sible for directing the myristoylated Pr55 Gag protein
to the host cell membrane where it embeds, aggregates
and buds off as VLPs which are “coated” in host cell
outer membrane [26,27]. Baculovirus produced Gag
VLPs (BV) were generated in Sf9 cells using the Bac-
to-Bac® Baculovirus Expression Vector System
[ 4 , 2 7 , 2 8 ] .B r i e f l y ,1×1 0
6 Sf9 cells/ml were infected
with baculovirus encoding human codon optimised
HIV-1 subtype C gag under control of the polh promo-
ter at a multiplicity of infection (MOI) of 2-10, and
VLPs were harvested from the culture supernatant
72 h post infection.
piggyBac plasmid constructs
The piggyBac minimal construct, pXLBacII has been
previously described [14,15]. pXLBacII contains a multi-
ple cloning site for insertion of a transgene between the
235 bp 3’ ITR (Inverse Terminal Repeat) and 310 bp 5’
ITR, but lacks the open reading frame encoding the pig-
gyBac transposase which is necessary for transposition
to occur. Instead, the piggyBac transposase open reading
frame is encoded on a separate helper plasmid. We used
as helper plasmids; pCasper-hs-orf (pCasper), in which
the transposase gene is controlled by the hsp70 promo-
ter, and pBSII-IE1-orf (pBSII-IE1), in which the transpo-
sase gene is controlled by the baculovirus immediate
early (ie1) promoter. These plasmids have been
described previously [15]. A transactivator plasmid
(hr3IE1) to be included as a third plasmid in transfec-
tion, was supplied by K.J. Maragathavally [29,30]. Con-
structs harboring different regulatory elements were
obtained from H. Zieler (see table 1) [31,32]. Constructs
containing a 133 bp intron placed upstream or down-
stream to the gag gene (409-FOR, 410-FOR, 411-FOR,
412-FOR), were included for comparison of Gag expres-
sion levels with and without the inclusion of an intron
[32].
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The human codon-optimised, myristoylated HIV-1 sub-
type C gag gene was coupled to different regulatory ele-
ments and cloned into the piggyBac minimal construct
pXLBacII, to be used in transfections (see table 1).
A digenic construct was designed to harbor the neo-
mycin gene coupled to the gag gene (NeoGag)t oe n a b l e
antibiotic selection of transgenic cells. This construct
was created by cloning the ie1-gag-polyA fragment from
the pXLBSII-IE1Gag construct, downstream of the neo
gene in pXLNeo (see table 1).
Transfection of Spodoptera frugiperda cells
Each of the pXLBacII constructs containing the gag or
NeoGag gene, together with one of the helper plasmids,
was co-transfected into Sf21 cells with Cellfectin (Invitro-
gen) for 5 hours. DNA amounts of 1 to 5 μg were used to
transfect 1.5 × 10
6 Sf21 cells per 2 ml, and the ratios of the
transgene to helper plasmids were varied from 1:1, 7:1 and
1:2 [33,34]. Two different helper plasmids, pCasper and
pBSII-IE1, were tested for differences in transgene integra-
tion as assessed by subsequent Gag expression levels. The
IE1 transactivator (hr3IE1) was included during transfec-
tion at a tenth of the total DNA amount to determine its
potential to improve promoter activity or transposition fre-
quency [29,30]. A comparison of transformability and
transgenic Gag expression levels was conducted between
three different insect cell lines, Sf21, Sf9 and High 5™.
PCR detection of the transgene and determination
of the integration event
DNA was extracted from ± 5 × 10
6 transgenic insect
cells using the Dneasy Tissue Extraction kit (Qiagen)
and subjected to PCR screening. Primers were designed
to amplify the transgenes (gag or neomycin) to assess
their presence and stability over several passages (see
table 2). To determine whether the entire piggyBac vec-
tor or only the transgene integrated into the insect cell
genome, primers were designed to amplify different
sites on the pXLBacII NeoGag vector. See table 2 for
the primer sequences and Figure 1 for their respective
positions on the vector. PCR screening was carried out
on a number of transgenic insect cell lines expressing
Gag under the control of various regulatory elements
(table 3).
Determination of whether Gag mRNA is transcribed from
an integrated transgene or from a persisting non-
integrated piggyBac vector plasmid
To confirm that the pXLBacII vector is absent from
the transgenic insect cell culture, and hence not con-
tributing to Gag expression, rolling circle amplifica-
tion (RCA, GE Healthcare, Amersham) was carried
out on DNA isolated from harvested cells. RCA is
based on a bacteriophage j29 DNA polymerase that
exponentially amplifies single- or double-stranded
circular DNA templates by rolling circle amplification.
To confirm the absence of inhibitory elements,
the isolated DNA sample was spiked with 0.7 ng
(± 7 × 10
7 copies) to 0.007 ng (± 7 × 10
5 copies) of
the pXLBacIINeoGag vector and amplified according
to the manufacturer’s protocol (GE Healthcare, Amer-
sham). Amplified products were subsequently digested
with Mlu1 (which cuts twice within the NeoGag
region) and analysed on a 0.8% agarose gel with ethi-
duim bromide staining.
Table 1 List of different regulatory elements used to design a set of gag piggyBac vector constructs
Construct Enhancer Promoter Intron upstream Gene Intron downstream PolyA Final pXLBacII construct
pHSP70 Drosophila hsp70 gag SV40sti/polyA pXLHSP70Gag
pIE1 hr5 Baculovirus AcMNPV ie1 gag (Heliothis) hel2polyA pXLIE1Gag
pIE1 hr5 Baculovirus AcMNPV ie1 Neo hel2polyA pXLNeo
pIE1-SV hr5 Baculovirus AcMNPV ie1 gag SV40sti/polyA pXLIE-SVGag
pActin Drosophila actin 5C gag hel2-polyA pXLActinGag
pActin-SV Drosophila actin 5C gag SV40sti/polyA pXLActin-SVGag
409-FOR hr5 Baculovirus AcMNPV ie1 + gag hel2polyA pXL409Gag
410-FOR hr5 Baculovirus AcMNPV ie1 gag + hel2polyA pXL410Gag
411-FOR Drosophila actin 5C + gag hel2-polyA pXL411Gag
412-FOR Drosophila actin 5C gag + hel2-polyA pXL412Gag
Hr3ieLuc hr3 Baculovirus AcMNPV ie1 gag pXlHr3ieGag
pBSII-IE1-orf Baculovirus AcMNPV ie1 gag pBSII-IE1-orf polyA pXLBSII-IE1Gag
The promoters tested included Drosophila hsp70, AcMNPV ie1a n dDrosophila actin 5C [30,31] (column 3). The promoter enhancers used were hr5 [31] and hr3
[30] (column 2). Poly-adenylation (polyA) sequences included SV40sti/polyA, hel2polyA [31] and a polyA tail isolated from the pBSII-IE1-orf helper plasmid [14,15]
(column 7). 409-FOR and 410-FOR are pIE1 vectors containing a 133 bp intron [32] (column 4 and 6) upstream or downstream of the gag gene, respectively. 411-
FOR and 412-FOR are pActin vectors containing the intron upstream or downstream of the gag gene, respectively. Briefly, different promoters, enhancers, polyA
sequences or the intron were removed from the construct described in column 1 and coupled to gag in the transposable pXLBacII vector [14,15] (column 8).
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To determine which method of transfection and which
regulatory variable generated a cell line capable of
secreting optimal Gag yields, cell supernatants were
screened for the p24 component of Gag using a p24
antigen ELISA kit (Vironostika, Biomeriuex) according
to the manufacturer’s instructions.
Selection assay
The NeoGag construct, together with the pCasper
helper, was transfected into Sf21 cells. Selection using 1
mg/ml geneticin (G418, Sigma) [7,6] began two days
post transfection. Transgenic cells were exposed to
geneticin after 40 passages (20 weeks) and examined for
viability using an inverted light microscope (Carl Zeiss
“Axioskop”). Non-transgenic cells were exposed to the
antibiotic and used as a negative control.
VLP isolation
piggyBac (PB)-produced VLPs were harvested from 1.5 ×
10
9 transgenic NeoGag insect cells and baculovirus pro-
duced (BV) VLPs were harvested from 24 × 10
7 baculo-
virus infected cells. Cell culture supernatants were
clarified by low speed centrifugation at 1000 g for 10
Figure 1 pXLBacIINeoGag vector. PCR products and amplification sites for the primers depicted in table 2 are indicated on the vector.
Table 2 Primer sequences used in the screening of transgenic insect cell lines expressing Gag protein
Primer pair Product
sense CTAAATTGTAAGCGTTAATATTTTG
antisense GGTAGCGACCCCCTCAGCCAATAAGAATTC
Product 1 (3’ITR and 3’ end of gag)
sense: GGGTTAATCTAGCTGCATCAGGATC
antisense: GAGCGCACGAGGGAGCTTC
Product 2 (5’ ITR)
sense: CTGGGATGGGTGGGTTGCTGG
antisense:CTTCTGAGAGCTCGATCGATAC
Product 3 (Junction between neomycin and gag)
sense ATGGGTGCTCGCGCATCTATCC
antisense ATTCTTGGCTGAGGGGGTCGC
Gag
sense GCGGTACCATGATTGAACAAG
antisense CGGAGCTCTCAGAAGAACTCG
Neomycin
sense CAGTTACCAATGCTTAATCAG
antisense GTATGAGTATTCAACATTTCCG
Ampicillin
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4°C by ultracentrifugation in a Beckman SW32ti rotor at
26 000 rpm for 90 minutes. The pellets were then resus-
pended in phosphate buffered saline (1 × PBS, pH 7.4)
and fractionated by centrifugation using a 10-50% Opti-
prep® (Sigma) step gradient at 26 000 rpm in a Beckman
SW32ti rotor for 4 hrs at 4°C. Three light-scattering
bands observed at the 10/20%, 20/30% and 30/40%
Optiprep® interphases (identical for both PB and BV
VLP preparations) were collected and pooled. VLPs
were pelleted, after dilution of the Optiprep® with PBS,
at 26 000 rpm for 90 minutes in a SW32ti rotor then
resuspended in l × PBS. Both PB and BV VLP prepara-
tions were confirmed negative for the presence of endo-
toxins (QCL-1000® Chromogenic LAL Kit, Cambrex).
Electron microscopy
Gradient purified samples were adsorbed onto carbon
coated copper grids, stained with 2% uranyl acetate and
visualized with a LEO 912 transmission electron
microscope.
Immunoblotting and quantification of PB and BV VLPs
The banding patterns of purified PB and BV VLP sam-
ples were analysed on Coomassie stained gels and anti-
p24 western blots. Aliquots of purified PB and BV VLPs
were fractionated by electrophoresis through a 10%
denaturing SDS polyacrylamide gel and either stained
with 0.1% Coomassie Blue stain to assess the relative
purity of the preparation, or blotted to a nitrocellulose
membrane (Nitrobond, Osmonics Inc.) using a semi-dry
electroblotter (Hoefer) for 1.5 h at 15 V. Pre-stained
molecular weight standards (PageRuler, Fermentas) and
a serial dilution of a HIV-1 Pr41 Gag positive control
(41 kDa; Quality Biological Inc., USA) was included on
the gel. Membranes were probed with 1:10 000 dilution
of anti-p24 rabbit antiserum (ARP432, NISBC Centra-
lised Facility for AIDS reagents, MRC, UK) followed by
a 1:5000 dilution of anti-rabbit alkaline phosphatase–
conjugated secondary antibody (Sigma). Membranes
were developed with Nitro blue tetrazolium chloride/5-
bromo-4-chloro-3-indolyl phosphate (NBT/BCIP,
Roche).
Gag concentrations were determined by comparing
calculated densities of the Pr55 bands in experimental
and control samples using gel imaging software
(Syngene). VLP concentrations were determined by cal-
culating densities of the Pr55 band on western blots
rather than using p24 ELISA quantification, as the Pr55
content is a more reliable indicator of the actual VLP
concentration in the sample than the p24 content. VLP
preparations were formulated with 15% trehalose to
100 ng Gag/100 μl PBS then stored at -70°C.
Baculovirus gp64 envelope glycoprotein content of
PB and BV VLPs was assessed by western blot analysis
as described above using a 1:10 000 dilution of anti-
baculovirus envelope gp64 antibody (Clone: AcV5,
eBioscience), followed by a 1:5000 dilution of anti-
mouse alkaline phosphatase–conjugated secondary
antibody (Sigma). Membranes were developed with
NBT, as above.
Immunization of mice and detection of cellular immune
responses
We compared the immunogenicity in BALB/c mice of
PB VLPs and BV VLPs when given alone, and their abil-
ity to boost a response to a prime with the matched
HIV-1 subtype C DNA vaccine, pTHgagC [24,25,35].
VLPs (100 ng Gag protein in 100 μlP B S )a n dD N A
(100 μgD N Ai n1 0 0μlP B S )w e r eg i v e nt og r o u p so f
female BALB/c mice (5 mice per group) via the intra-
muscular route with 50 μl injected into each quadriceps
muscle. To test responses to VLPs alone, mice were
i n o c u l a t e dw i t has i n g l ed o s eo fe i t h e rPB Gag VLPs or
BV Gag VLPs on day 0, and spleens from VLP-inocu-
lated mice were harvested on day 12. To assess VLP
Table 3 PCR screening results of transgenic insect cell lines
Construct Product 1 Product 2 Product 3 gag Neo Amp
pXLNeoGag passage 15 in Sf21 cells + + + + + +
pXLNeoGag passage 26 in Sf21 cells + + + + + +
pXLNeoGag passage 23 in Sf9 cells X + + + + +
passage 7 +
passage 13 +
passage 93 +
pXLIE-SVGag passage 16 in Sf21 cells X + X + X +
pXlHr3ieGag passage 9 in Sf21 cells X + X + X +
pXLHSP70Gag passage 6 in Sf21 cells X + X + X +
Screening was carried out using primers complementary to different sections of the pXLBacIINeoGag vector. The presence of a PCR product is indicated with a
plus (+) and absence with a cross (X). Confirmation of stable integration up to 93 passages was indicated by performing PCR amplification on several passages of
pXLNeoGag in Sf9 cells (see bold font).
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of pTHGagC on day 0 and boosted with a single dose of
either PB Gag VLPs or BV Gag VLPs given on day 28
and spleens were harvested on day 40. Mice vaccinated
with pTHGagC on day 0 without any boosting on day
28 were used as a DNA primed, unboosted control
group and their spleens were likewise harvested on day
40. All procedures were carried out according to guide-
lines and with approval of the UCT Animal Research
Ethics Committee. Cell mediated immune responses
were determined using splenocytes in Interferon gamma
(IFN-g) and interleukin 2 (IL-2) ELISPOT assays (BD
Pharmingen) with Gag CD8 peptide (AMQMLKDTI),
and Gag CD4 (13) and Gag CD4 (17) peptides
(NPPIPVGRIYKRWIILGLNK and FRDYVDRFFKTL-
RAEQATQE, respectively) as previously described [27].
Results
Transgene expression
p24 ELISA was used to screen the culture supernatants
from different transgenic cell lines maintained in cul-
ture. All preliminary experiments were carried out in
Sf21, Sf9 and High 5™ cell lines in order to confirm
that these lines were amenable to piggyBac transforma-
tion and subsequent Gag VLP expression. For reasons
of practical handling, all further experiments were car-
ried out using only Sf21 cell lines, for small scale
amplification, and Sf9 cell lines, for large scale amplifi-
cation (Sf9 cells being more suitable to this because
they were maintained as a shaking culture versus Sf21
cells that were maintained as a monolayer culture).
Sf21 cells and Sf9 cells expressed the Gag protein at
similar levels for each construct tested. The highest
p24 expression level obtained was from cell lines trans-
genic for the gag gene coupled to the ie1p r o m o t e ra n d
the pBSII-IE1 polyA tail (derived from pXLBacSII-
IE1Gag). Expression from these cell lines ranged
between 100-1000 pg per 1.5 × 10
6 cells. Previous
work suggested that inclusion of an intron adjacent to
a gene can stimulate its transcription and possibly
enhance protein expression levels [32]. No significant
expression variations were observed when the same
intron was used in this study. No p24 expression was
evident when the gag gene was placed under the hsp70
or actin 5C promoters. Further investigation into
transgenic hsp70-gag cell lines confirmed the integra-
tion of the construct (see table 3) ruling out the possi-
bility that no transgene integration had occurred.
Inclusion of a third plasmid expressing a transactiva-
tor is known to improve protein expression levels by
enhancing promoter activity [30] or by increasing trans-
positional frequency of the element [29]. No significant
variation in Gag expression was observed when the IE1
transactivator was included at transfection. Use of differ-
ent helper plasmids and transfection ratios did not affect
the expression either.
Persistence of expression
Transgenic Sf21 and Sf9 cell lines continued to express
Gag protein at constant levels (as determined using p24
ELISA) for at least 100 cell passages. Table 3 and 4 indi-
cate the PCR amplification results determined for sev-
eral transgenic insect cell lines. PCR amplification of the
gag transgene from insect cell genomic DNA remained
positive after 93 cell passages. PCR amplification of the
neomycin transgene from insect cell genomic DNA
remained positive for 30 cell passages and was not
tested further. Exposure of the Sf21 NeoGag cells to
geneticin at passage 40 had no effect on their survival,
which was in contrast to the non-transgenic control
cells that lost viability within three to four days. The
geneticin was not administered prior to passage 40 indi-
cating that it is not a requirement for stable integration.
These results strongly indicate stable integration and
expression of the transgene over many cell generations.
Integration of the piggyBac vector
To examine the nature of the integration event that had
occurred, PCR screening of the piggyBac vector and the
transgenes was carried out on several transgenic insect cell
lines. Table 3 indicates the absence or presence of the
PCR products in selected cell lines (refer to table 2). Pro-
duct 1 is an amplification of the 3’ end of the gag gene and
the 3’ piggyBac border (3’ ITR), product 2 is an amplifica-
tion of the 5’ piggyBac border (5’ ITR). Product 1 and 2
would be absent if canonical piggyBac transposon
Table 4 Continuous expression of p24 protein from several transgenic insect cell lines as determined by ELISA
Cell line and passage number gag transgene presence (PCR) Gag expression:
pg p24/ml culture supernatant (1.5 × 10
6 cells)
pXLNeoGag passage 7 in Sf9 cells + 129.87 pg/ml
pXLNeoGag passage 13 in Sf9 cells + 129 pg/ml
pXLNeoGag passage 23 in Sf9 cells + 75.47 pg/ml
pXLNeoGag passage 93 in Sf9 cells + 606.6 pg/ml
The presence and active transcription of the gag transgene in the Sf9 cell line pXLNeoGag, was confirmed over several passages using PCR and p24 ELISA
screening, respectively.
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neomycin gene and the 5’ end of the gag gene, providing
evidence of transgene integrity. The majority of results
indicate that the plasmid was linearised at the 3’ ITR prior
to integration of the entire intact piggyBac plasmid, possi-
bly through a recombination mechanism unrelated to
tranposition. A study in Aedes aegypti using piggyBac
transformation revealed similar non-canonical integration
of sequences from both donor and helper plasmids
[22,36]. No evidence of helper plasmid integration was evi-
dent in our study as confirmed by PCR screening for the
hsp70 promoter in transgenic cell lines transfected with
the pCasper helper plasmid (data not shown). However,
these results are inconclusive in predicting whether
recombination or transposon insertion occurred, as single
insect cell clones were not isolated post transfection and
mixed populations may exist.
Gag expression is not due to persisting non-integrated
plasmid
Rolling circle amplification (RCA) was carried out on
DNA extracted from transgenic Sf21 NeoGag cells to
eliminate the possibility of transient Gag expression
from a persistent non-integrated circular piggyBac vec-
tor. As seen in Figure 2, lane 3, no circular DNA that
resembled the pXLBacIINeoGag plasmid (lane 2) was
detected in the transgenic DNA sample. The minimum
amount of pUC19 DNA that can be amplified using
R C Ai s1p g( ±3×1 0 5c o p i e s )( R C Ai n s t r u c t i o nm a n -
ual, GE Healthcare, Amersham). To discount the possi-
bility that non-amplification could be attributed to a low
copy of the circularised DNA or the presence of inhibi-
tors in the isolated DNA sample, transgenic insect DNA
extract was spiked with 10-fold dilutions of the pXLBa-
cIINeoGag plasmid prior to amplification. A minimum
Figure 2 RCA amplification carried out on DNA extracted from NeoGag expressing transgenic cells. The RCA product was digested with
Mlu1 and visualised on an 0.8% agarose gel. Lane 1- Fermentas Bioline hyperladder 1 with sizes indicated in basepairs. Lane 2- positive control
(pXLBacIINeoGag). Lane 3- Sf21 NeoGag genomic DNA. Lane 4- Sf21 NeoGag genomic DNA spiked with 7 ng of the positive control. Lane 5- Sf21
NeoGag genomic DNA spiked with 700 pg of positive control. Lane 6- Sf21 NeoGag genomic DNA spiked with 70 pg of positive control. Lane 7-
Sf21 NeoGag genomic DNA spiked with 7 pg of positive control.
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6 copies) of spiked construct was
detectable. No amplification of 7 pg of spiked plasmid
(± 7 × 10
5 copies) occurred. This copy number
approaches the limits of detectability for the RCA assay.
Together these results suggest that absence of detectable
RCA amplification in transgenic Sf21 NeoGag cells is
not due to inhibitor presence but is rather due to
absence of non-integrated plasmid in the samples.
Size and morphology of PB and BV VLPs
EM analysis of the three protein bands isolated from
the PB and BV gradients revealed particles of size
120-150 nm in the 10/20% and 20/30% Optiprep® inter-
phases. VLP size range and morphology resembled that
of VLPs previously reported [3,4,27]. PB VLPs and BV
VLPs were similar in size and shape although BV VLPs
appeared more defined and compact than the PB VLPs
(see Figure 3).
Western blot immunodetection and quantification of PB
and BV VLPs
Purified Gag VLPs extracted from the transgenic cell
culture and from recombinant baculovirus infected cells
were analysed and quantified on an anti-p24 western
blot using densitometry. An identical Pr55 Gag
band was detected in both PB and BV VLP preparations
(Figure 4A). Quantification of purified PB VLPs on
western blots against a serial dilution of a HIV-1 Pr41
positive control indicated yields of 1-2 ng per 1 × 10
6
Sf9 cells, at least 1000 times lower than yields obtained
for BV expressed VLPs. Anti-gp64 western blot results
show the absence of gp64 envelope protein in PB
VLP samples and its presence in BV VLP samples
(Figure 4B).
As seen in Figure 5, the Pr55 Gag protein of the BV
VLP sample was readily detected on a Coomassie
stained gel as well as on an anti-p24 western blot. The
Pr55 Gag protein of the PB VLP sample was detected at
the same protein size location on the anti-p24 western
blot, but was not detectable against the background on
the Coomassie stained gel, as was expected given the
low p24 concentration of the loaded sample).
Immunogenicity of VLPs
It has previously been shown that BV Gag VLPs
enhance a cellular immune response in mice when used
as a boost to a pTHgagC DNA prime [4,27]. To assess
whether the PB VLPs elicited a similar response in the
absence of baculovirus elements, mice were inoculated
with equal quantities of either BV or PB VLPs. Because
the study reported here was designed in proof of con-
cept, we conducted only a standard heterologous prime-
boost immunogenicity experiment, in which we com-
pared the boost potential of PB VLPs versus BV VLPs,
using the same dosage which our group had previously
found optimal when using BV VLPs to elicit a boosted
immunological response in DNA inoculated mice: that
is, 100 ng of HIV-1C VLPs administered as 2 × 50 ng
inoculated into each quadriceps muscle alone or as a
boost to DNA primed mouse at day 28 (ms. submitted;
S Pillay, A Meyers, EG Shephard, A-L Williamson, EP
Rybicki). IFN-g and IL-2 ELISPOT analysis (Figure 6)
showed that PB VLPs did not induce an immune
response nor did they boost an immune response to a
DNA vaccine prime. In contrast the ELISPOT assays
detected a low magnitude of GagCD4(13)-specific IFNg
and IL-2 producing cells but no GagCD8-specific cells
in response to BV VLP vaccination. These BV VLPs
boosted pTHGagC responses. A 1.8 fold increase in the
response to the GagCD8 peptide was detected in the
IFN-g ELISPOT assay. The low cumulative response to
the GagCD4(13) and GagCD4(17) peptide of 50 IFN-g
sfu/10
6 splenocytes induced by pTHGagC increased 12
fold to 602 sfu/10
6 splenocytes when pTHgagC primed
Figure 3 Electron micrographs of PB and BV VLPs.A :PB VLPs, scale bar 500 nm. B: BV VLPs, same scale. Arrows show contamination by
co-purified recombinant baculovirus in the BV sample. Insets: individual particles with diameter shown. PB VLP: 139 nm; BV VLP: 129 nm.
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Page 8 of 13mice were boosted with these BV VLPs. No boost of the
DNA vaccine induced GagCD8 response was detected
in IL-2 assays. Although pTHgagC did not induce Gag-
specific CD4+ T cells that produced IL-2, a high cumu-
lative magnitude of 390 sfu/10
6 splenocytes Gag-specific
CD4(13) and GagCD4(17) T cells producing IL-2 was
detected in response to a DNA prime BV VLP boost.
Discussion
Gag epitopes elicit robust CTL responses that effectively
control HIV-1 viral load in the early phases of HIV-1
infection, and Gag is therefore thought to be highly sui-
table as a vaccine candidate to elicit CTL [3]. HIV-1
Gag VLPs, in particular, are widely accepted as being
strongly immunogenic particulate antigens that stimu-
late good CTL responses in prime/boost vaccination
strategies [3-5,27,37]. Baculovirus production of HIV-1
Gag VLPs is a well documented method for generating
immunogenic HIV-1 particles, but contamination of
VLPs with co-purified baculovirus particles (Figure 3) is
not favourable for their subsequent use in vaccine stu-
dies. To address this problem and the problem of
Figure 4 Western blot immunodetection of PB and BV VLPs. A: Anti-p24 western blot. Lane 1-1.2 ng Pr41 std. Lane 2-2.4 ng Pr41 std. Lane
3-4.8 ng Pr41 std. Lane 4-7.2 ng Pr41 std. Lane 5- purified PB VLPs from the 20/30% Optiprep® interphase (22 ug of total soluble protein loaded).
Lane 6- purified BV VLPs from the 20/30% Optiprep® interphase (0.68 ug of total soluble protein loaded). B: Anti-gp64 western blot. Lane 1-
Supernatant from cells infected with negative baculovirus (no gag insert). Lane 2- purified PB VLPs from the 10/20% Optiprep® interphase. Lane
3- purified PB VLPs from the 20/30% Optiprep® interphase. Lane 4- purified BV VLPs from the 20/30% Optiprep® interphase. The respective sizes
from markers run on the same gels are indicated in kDA on the left of both blots.
Figure 5 Comparison of PB and BV VLP banding pattern differences as visualised on a Coomassie stained gel and western blot.
Coomassie Blue stained 10% denaturing polyacrylamide gels are shown on the left of 5A and 5B and anti-p24 stained western blots are shown
on the right of 5A and 5B. Protein size markers on gels and blots are indicated in kDA. Red arrows indicate the Gag Pr55 band. A- Purified PB
VLPs. Lanes 1 and 4 - MW marker. Lane 2- Coomassie Blue stained PB VLP preparation (30 ul of purified sample, corresponding to 6 pg p24).
Lane 3- PB VLP preparation detected with anti-p24 antibody (30 ul of purified sample, corresponding to 6 pg p24). B- Purified BV VLPs. Lanes 1
and 4 - MW marker. Lane 2- Coomassie Blue stained BV VLP preparation (28 ul of purified sample, corresponding to 170 ng p24). Lane 3- BV VLP
detected with anti-p24 antibody (28 ul of purified sample, corresponding to 17 ng p24).
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Page 9 of 13routine maintenance of infectious stocks, we utilised pig-
gyBac transposon mutagenesis as a novel method of
generating gag-transgenic insect cell lines for continuous
production of HIV-1 Gag VLPs. Expression of Gag
VLPs from these transgenic cell lines proved stable for
at least 100 cell passages: this is a novel result, which
may have valuable implications in future HIV and other
vaccine work.
Using immunodetection and EM we verified that Gag
VLPs were secreted from transgenic insect cell lines.
However, the yields were low (at least 1000 times lower
than from the baculovirus production system) and
therefore we tested the ability of various regulatory ele-
ments to improve protein expression of the gag trans-
gene. No improvement in Gag protein expression was
n o t e dw h e nw ec l o n e dh r 5a n dh r 3b a c u l o v i r u s - d e r i v e d
enhancer elements [38] or introns [32] into the piggyBac
construct, nor when we included the transactivator dur-
ing transfection [30,39]. Different molar transposase-to-
transposon ratios did not affect Gag expression levels,
A
0
100
200
300
400
500
med Irrel Pept gagCD8 gagCD4(13) gagCD4(17)
HIV-1 peptides
s
f
u
/
1
0
6
 
p
l
e
n
o
c
y
t
e
s
pTHGagx1 (D40)
pTHGagx1+PBGagVLP(D40)
pTHGagx1+BVGagVLP(D40)
PBGagVLP (D12)
BVGagVLP (D12)
B
0
50
100
150
200
250
300
med Irrel Pept gagCD8 gagCD4(13) gagCD4(17)
HIV-1 peptides
s
f
u
/
1
0
6
 
s
p
l
e
n
o
y
c
t
e
s
pTHGagx1 (D40)
pTHGagx1+PBGagVLP(D40)
pTHGagx1+BVGagVLP(D40)
PBGagVLP (D12)
BVGagVLP (D12)
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Page 10 of 13which also confirms previous observations that the pig-
gyBac system does not demonstrate overproduction
inhibition [20]. In preliminary experiments, we noted
that the hsp70 or actin 5C promoters were not active in
the Spodoptera transgenic cell lines, and so no further
work was done with these constructs. The Bombyx mori
actin 3C promoter and Drosophila ubiquitin promoter
have proven active in a variety of insect species [13] and
should be evaluated in Spodoptera insect cell culture as
an alternative means to possibly improve transgene
expression.
Although Gag VLP yields obtained in this preliminary
study were low, we are confident that there are several
approaches that can be employed to improve protein
expression yields. Inclusion of a Gal4 DNA binding
domain as an N-terminal fusion to the transposon has
been shown to increase the number of transposition
events [40] which in turn can result in improved protein
expression levels. It has been shown recently that the
translation enhancer activity of 5’-UTR pol (un-trans-
lated region of the nucleopolyhedrovirus polyhedron
gene) is able to improve transgene expression when
placed upstream to the promoter [41]. Poor transgene
expression could be attributed potentially to the integra-
tion of the gene into an unfavourable genomic site such
as a silent heterochromatin region or near to unfavour-
able transcription enhancers. This can be overcome by
directing the transposon construct to a targeted site
using the Gal4/UAS or FLP/FRT system [40,42,43], or
by surrounding the transgene with an insulator [44].
Transposon constructs can be designed to harbour
bidirectional promoters that drive simultaneous expres-
sion of the transgene and a strong artificial transcrip-
tional activator [45], leading to improved transgene
expression levels.
However, it is possible that constitutive production of
Gag protein is toxic to the cell, so only low expressers
survive. In this case, inducible expression systems could
be explored.
We conducted a comparative study in mice to assess
t h er e l a t i v ei m m u n o g e n i c i t yo fb a c u l o v i r u s - p r o d u c e d
VLPs versus piggyBac transgenically expressed VLPs.
While BV VLPs were able to induce a good CD4
immune response in mice when administered as a
boost to a DNA prime, PB VLPs, on the other hand,
elicited no immune response, showing that Gag VLPs
are not intrinsically as highly immunogenic as pre-
viously thought, and that baculovirus-derived elements
probably enhance Gag VLP immunogenicity. Baculo-
virus-expressed Gag VLPs include trace amounts of
insect cell and baculoviral contaminants (lipids, nucleic
acids and proteins) that are not efficiently removed
during purification, as well as incorporated baculovirus
envelope proteins. Deml et al proposed that these
contaminating components act as “danger signals” that
can activate an innate immune response [3,26]. It has
also been shown that VLPs isolated from yeast [46] as
well as from the baculovirus expression system [3]
contain host cellular contaminants capable of stimulat-
ing human antigen presenting cells (APC) by up-regu-
lating the maturation of cytotoxic T lymphocyte (CTL)
markers and inducing cytokine secretion. Although it
was beyond the ambit of the current study, it would be
interesting to compare the relative ability of PB VLPs
and BV VLPs to stimulate dendr i t i cc e l l s ,a st h i sc o u l d
provide insight into the observed differences in immu-
nogenicity between PB and BV VLPs in the study
reported here.
Baculovirus has been shown to transduce mamma-
lian cells, which could lead to adjuvanting of immune
responses [47,48]. A recent study showed that intrana-
sal inoculation of mice with a wild-type baculovirus
induces a strong innate immune response, which pro-
tects mice from a lethal challenge of influenza virus
[49]. Cellular uptake of baculovirus and subsequent
immune response enhancement may be due largely to
t h ep r e s e n c eo ft h eI F N - s t i m u l a t o r yb a c u l o v i r u ss u r -
face envelope glycoprotein gp64, which is responsible
for host cell receptor binding and membrane fusion
during viral entry by endocytosis [50]. In particular,
gp64 protein is known to incorporate into the outer
surface of baculovirus expressed Gag VLPs
[3,26,47,51]. This has been additionally demonstrated
in the current study, where both BV VLPs and PB
VLPs are “coated” in host cell outer membrane, but
gp64 would be available for incorporation only into
t h eB VV L P s( F i g u r e4 ) .W eo b s e r v e dt h a tw h i l ePB
VLPs were similar in size and morphology to BV
VLPs, as seen by EM, they did not appear to be as
compact or sharply defined in shape as BV VLPs (Fig-
ure 3). Since PB VLPs lacked baculovirus gp64 incor-
poration into the VLPs outer membrane coating, the
more defined shape of the BV VLPs compared to that
of the PB V L P sm a yb ea c c o u n t e df o rb yt h ei n c o r -
poration of gp64 into the BV VLP outer membrane. It
is likely that incorporation of gp64 onto the surface of
baculovirus expressed VLPs facilitates BV VLP uptake
into APC by promoting membrane fusion between BV
VLPs and host cells, thereby enhancing the resultant
immune response to VLP Gag antigens conditioned by
APCs. Transgenically produced VLPs lack gp64 and
this may result in less efficient cellular uptake of VLPs,
with resultant lower immunogenicity.
The use of molecular adjuvants or incorporation of
gp64 onto VLP surfaces could be utilised to improve the
immunogenicity of these particles expressed from trans-
genic insect cell lines. Shi et al. [33] demonstrated the
use of piggyBac transposon vectors to transiently express
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Page 11 of 13two gene products. In this system, the two genes were
placed under the control of bidirectional promoters
w h i c hi nt u r nw e r ee n h a n c e db yas i n g l ee n h a n c e re l e -
ment. Such dual expression systems could be used to
co-express immune enhancer elements [52] or immuno-
genic baculovirus elements together with HIV-1 Gag
VLPs to improve VLP immunogenicity.
Once a cell line has been established that transgeni-
cally expresses Gag VLPs at a high level and with
enhanced immunogenicity features, permanent stabilisa-
tion of the transgene in piggyBac-transformed insect cell
lines would be carried out by transgene integration site
elimination. It has been demonstrated that elimination
of the piggyBac transposon integration sites adjacent to
the integrated transgene renders the element immobile
to further transposase exposure [43,53].
Conclusion
This study serves as a basis to indicate the potential of a
transgenic insect cell expression system as an alternative
to the baculovirus-insect cell production system. Stably
transformed cells produced VLPs reliably over 100 pas-
sages; purification of VLPs was also easier than in the
baculovirus system due to lack of heterologous virus
particles. However, further work is needed to improve
VLP expression levels and their immunogenicity.
Acknowledgements
We acknowledge with thanks the kind donation of plasmids by C Coates
and KJ Maragathavally, 110, Heep Center, Entomology Department Texas
A&M University, College Station, TX 77843-2475; and H Zieler, Medical
Entomology Section Laboratory of Parasitic Diseases, National Institute of
Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
20892-0425, USA. We are grateful to Rodney Lucas for mouse inoculations
and Anke Binder, Desiree Bowers, and Zaahier Isaacs for doing the
immunology assays. We thank Ann Meyers for help with protein assays. We
also thank Mohammed Jaffer for assistance with the EM analysis. This work
was funded by the South African AIDS Vaccine Initiative (SAAVI). Murine
immunology procedures were done according to UCT ethics guidelines
(AEC code 006-007).
Author details
1Department of Molecular and Cell Biology, Faculty of Science, University of
Cape Town, Rondebosch, Cape Town, South Africa.
2Institute of Infectious
Disease and Molecular Medicine, Faculty of Health Sciences, University of
Cape Town, Observatory, Cape Town, South Africa.
3MRC/UCT Liver Research
Centre, Department of Medicine, Faculty of Health Sciences, University of
Cape Town, Observatory, Cape Town, South Africa.
4National Health
Laboratory Service, Groote Schuur Hospital, Observatory, Cape Town, South
Africa.
5Department of Biological Sciences, University of Notre Dame, Notre
Dame, IN46556-0369, USA.
Authors’ contributions
AL participated in the design of the study, carried out most of the
experimental work and drafted the manuscript. FT conceived the study,
participated in the design of the study, and helped in drafting and revising
the manuscript. ES performed the immunological experiments described in
the study and participated in experimental design. MF provided the
piggyBac transposons and protocols and helped with the ms. A-LW was
overall study director and obtained the funding, and helped in drafting the
ms. EPR participated in study design and supervision and helped to revise
the manuscript. All authors read and approved the final version.
Received: 12 October 2009 Accepted: 31 March 2010
Published: 31 March 2010
References
1. UNAIDS (2007). UNAIDS AIDS Epidemic Update: November 2007.
2. Wagner R, Deml L, Schirmbeck R, Niedrig M, Reimann J, Wolf H:
Construction, expression, and immunogenicity of chimeric HIV-1 virus-
like particles. Virology 1996, 220:128-140.
3. Deml L, Speth C, Dierich MP, Wolf H, Wagner R: Recombinant HIV-1 Pr55
gag virus-like particles: potent stimulators of innate and acquired
immune responses. Mol Immunol 2005, 42:259-277.
4. Jaffray A, Shephard E, van HJ, Williamson C, Williamson AL, Rybicki EP:
Human immunodeficiency virus type 1 subtype C Gag virus-like particle
boost substantially improves the immune response to a subtype C gag
DNA vaccine in mice. J Gen Virol 2004, 85:409-413.
5. Chege GK, Shephard EG, Meyers A, van HJ, Williamson C, Lynch A, Gray CM,
Rybicki EP, Williamson AL: HIV-1 subtype C Pr55 gag virus-like particle
vaccine efficiently boosts baboons primed with a matched DNA vaccine.
J Gen Virol 2008, 89:2214-2227.
6. McCarroll L, King LA: Stable insect cell cultures for recombinant protein
production. Curr Opin Biotechnol 1997, 8:590-594.
7. Joyce KA, Atkinson AE, Bermudez I, Beadle DJ, King LA: Synthesis of
functional GABAA receptors in stable insect cell lines. FEBS Lett 1993,
335:61-64.
8. Hollister J, Grabenhorst E, Nimtz M, Conradt H, Jarvis DL: Engineering the
protein N-glycosylation pathway in insect cells for production of
biantennary, complex N-glycans. Biochemistry 2002, 41:15093-15104.
9. Breitbach K, Jarvis DL: Improved glycosylation of a foreign protein by Tn-
5B1-4 cells engineered to express mammalian glycosyltransferases.
Biotechnol Bioeng 2001, 74:230-239.
10. Aumiller JJ, Hollister JR, Jarvis DL: A transgenic insect cell line engineered
to produce CMP-sialic acid and sialylated glycoproteins. Glycobiology
2003, 13:497-507.
11. McLachlin JR, Miller LK: Stable transformation of insect cells to coexpress
a rapidly selectable marker gene and an inhibitor of apoptosis. In Vitro
Cell Dev Biol Anim 1997, 33:575-579.
12. Ding S, Wu X, Li G, Han M, Zhuang Y, Xu T: Efficient transposition of the
piggyBac (PB) transposon in mammalian cells and mice. Cell 2005,
122:473-483.
13. Handler AM: Use of the piggyBac transposon for germ-line
transformation of insects. Insect Biochem Mol Biol 2002, 32:1211-1220.
14. The piggyBac. 2008 [http://piggybac.bio.nd.edu/].
15. Fraser MJ, Cary L, Boonvisudhi K, Wang HG: Assay for movement of
Lepidopteran transposon IFP2 in insect cells using a baculovirus
genome as a target DNA. Virology 1995, 211:397-407.
16. Bossin H, Furlong RB, Gillett JL, Bergoin M, Shirk PD: Somatic
transformation efficiencies and expression patterns using the JcDNV and
piggyBac transposon gene vectors in insects. Insect Mol Biol 2007,
16:37-47.
17. Li X, Harrell RA, Handler AM, Beam T, Hennessy K, Fraser MJ Jr: piggyBac
internal sequences are necessary for efficient transformation of target
genomes. Insect Mol Biol 2005, 14:17-30.
18. Condon KC, Condon GC, Dafa’alla TH, Forrester OT, Phillips CE, Scaife S,
Alphey L: Germ-line transformation of the Mexican fruit fly. Insect Mol Biol
2007, 16:573-580.
19. Mitra R, Fain-Thornton J, Craig NL: piggyBac can bypass DNA synthesis
during cut and paste transposition. EMBO J 2008, 27:1097-1109.
20. Wilson MH, Coates CJ, George AL Jr: PiggyBac transposon-mediated gene
transfer in human cells. Mol Ther 2007, 15:139-145.
21. Handler AM, McCombs SD: The piggyBac transposon mediates germ-line
transformation in the Oriental fruit fly and closely related elements exist
in its genome. Insect Mol Biol 2000, 9:605-612.
22. O’Brochta DA, Sethuraman N, Wilson R, Hice RH, Pinkerton AC,
Levesque CS, Bideshi DK, Jasinskiene N, Coates CJ, James AA, et al: Gene
vector and transposable element behavior in mosquitoes. J Exp Biol
2003, 206:3823-3834.
23. Peloquin JJ, Thibault ST, Staten R, Miller TA: Germ-line transformation of
pink bollworm (Lepidoptera: gelechiidae) mediated by the piggyBac
transposable element. Insect Mol Biol 2000, 9:323-333.
24. Williamson C, Morris L, Maughan MF, Ping LH, Dryga SA, Thomas R,
Reap EA, Cilliers T, van HJ, Pascual A, et al: Characterization and selection
Lynch et al. BMC Biotechnology 2010, 10:30
http://www.biomedcentral.com/1472-6750/10/30
Page 12 of 13of HIV-1 subtype C isolates for use in vaccine development. AIDS Res
Hum Retroviruses 2003, 19:133-144.
25. van Harmelen JH, Shephard E, Thomas R, Hanke T, Williamson AL,
Williamson C: Construction and characterisation of a candidate HIV-1
subtype C DNA vaccine for South Africa. Vaccine 2003, 21:4380-4389.
26. Ludwig C, Wagner R: Virus-like particles-universal molecular toolboxes.
Curr Opin Biotechnol 2007, 18:537-545.
27. Halsey RJ, Tanzer FL, Meyers A, Pillay S, Lynch A, Shephard E, Williamson AL,
Rybicki EP: Chimaeric HIV-1 subtype C Gag molecules with large in-frame
C-terminal polypeptide fusions form virus-like particles. Virus Res 2008,
133:259-268.
28. O’Reilly DR, Miller LK, Luckow VA: Baculovirus Expression Vectors, A
Laboratory Manual. Oxford University Press. Inc 1994.
29. Mohammed A, Coates CJ: Promoter and piggyBac activities within
embryos of the potato tuber moth, Phthorimaea operculella, Zeller
(Lepidoptera: Gelechiidae). Gene 2004, 342:293-301.
30. Gray CE, Coates CJ: High-level gene expression in Aedes albopictus cells
using a baculovirus Hr3 enhancer and IE1 transactivator. BMC Mol Biol
2004, 5:8.
31. Huynh CQ, Zieler H: Construction of modular and versatile plasmid
vectors for the high-level expression of single or multiple genes in
insects and insect cell lines. J Mol Biol 1999, 288:13-20.
32. Zieler H, Huynh CQ: Intron-dependent stimulation of marker gene
expression in cultured insect cells. Insect Mol Biol 2002, 11:87-95.
33. Shi X, Harrison RL, Hollister JR, Mohammed A, Fraser MJ Jr, Jarvis DL:
Construction and characterization of new piggyBac vectors for
constitutive or inducible expression of heterologous gene pairs and the
identification of a previously unrecognized activator sequence in
piggyBac. BMC Biotechnol 2007, 7:5.
34. Handler AM, Harrell RA: Germline transformation of Drosophila
melanogaster with the piggyBac transposon vector. Insect Mol Biol 1999,
8:449-457.
35. Burgers WA, van Harmelen JH, Shephard E, Adams C, Mgwebi T, Bourn W,
Hanke T, Williamson AL, Williamson C: Design and preclinical evaluation of
a multigene human immunodeficiency virus type 1 subtype C DNA
vaccine for clinical trial. J Gen Virol 2006, 87:399-410.
36. Adelman ZN, Jasinskiene N, Vally KJ, Peek C, Travanty EA, Olson KE,
Brown SE, Stephens JL, Knudson DL, Coates CJ, et al: Formation and loss
of large, unstable tandem arrays of the piggyBac transposable element
in the yellow fever mosquito, Aedes aegypti. Transgenic Res 2004,
13:411-425.
37. Wagner R, Deml L, Teeuwsen V, Heeney J, Yiming S, Wolf H: A
recombinant HIV-1 virus-like particle vaccine: from concepts to a field
study. Antibiot Chemother 1996, 48:68-83.
38. Jarvis DL, Weinkauf C, Guarino LA: Immediate-early baculovirus vectors for
foreign gene expression in transformed or infected insect cells. Protein
Expr Purif 1996, 8:191-203.
39. Leisy DJ, Rasmussen C, Owusu EO, Rohrmann GF: A mechanism for
negative gene regulation in Autographa californica multinucleocapsid
nuclear polyhedrosis virus. J Virol 1997, 71:5088-5094.
40. Maragathavally KJ, Kaminski JM, Coates CJ: Chimeric Mos1 and piggyBac
transposases result in site-directed integration. FASEB J 2006,
20:1880-1882.
41. Iizuka M, Tomita M, Shimizu K, Kikuchi Y, Yoshizato K: Translational
enhancement of recombinant protein synthesis in transgenic silkworms
by a 5’-untranslated region of polyhedrin gene of Bombyx mori
Nucleopolyhedrovirus. J Biosci Bioeng 2008, 105:595-603.
42. Imamura M, Nakai J, Inoue S, Quan GX, Kanda T, Tamura T: Targeted gene
expression using the GAL4/UAS system in the silkworm Bombyx mori.
Genetics 2003, 165:1329-1340.
43. Horn C, Handler AM: Site-specific genomic targeting in Drosophila. Proc
Natl Acad Sci USA 2005, 102:12483-12488.
44. Sarkar A, Atapattu A, Belikoff EJ, Heinrich JC, Li X, Horn C, Wimmer EA,
Scott MJ: Insulated piggyBac vectors for insect transgenesis. BMC
Biotechnol 2006, 6:27.
45. Liu B, Paton JF, Kasparov S: Viral vectors based on bidirectional cell-
specific mammalian promoters and transcriptional amplification strategy
for use in vitro and in vivo. BMC Biotechnol 2008, 8:49.
46. Tsunetsugu-Yokota Y, Morikawa Y, Isogai M, Kawana-Tachikawa A,
Odawara T, Nakamura T, Grassi F, Autran B, Iwamoto A: Yeast-derived
human immunodeficiency virus type 1 p55(gag) virus-like particles
activate dendritic cells (DCs) and induce perforin expression in Gag-
specific CD8(+) T cells by cross-presentation of DCs. J Virol 2003,
77:10250-10259.
47. Hu YC: Baculovirus as a highly efficient expression vector in insect and
mammalian cells. Acta Pharmacol Sin 2005, 26:405-416.
48. Sinn PL, Burnight ER, Hickey MA, Blissard GW, McCray PB Jr: Persistent gene
expression in mouse nasal epithelia following feline immunodeficiency
virus-based vector gene transfer. J Virol 2005, 79:12818-12827.
49. Abe T, Takahashi H, Hamazaki H, Miyano-Kurosaki N, Matsuura Y, Takaku H:
Baculovirus induces an innate immune response and confers protection
from lethal influenza virus infection in mice. J Immunol 2003,
171:1133-1139.
50. Li Z, Blissard GW: Functional analysis of the transmembrane (TM) domain
of the Autographa californica multicapsid nucleopolyhedrovirus GP64
protein: substitution of heterologous TM domains. J Virol 2008,
82:3329-3341.
51. Hervas-Stubbs S, Rueda P, Lopez L, Leclerc C: Insect baculoviruses
strongly potentiate adaptive immune responses by inducing type I IFN.
J Immunol 2007, 178:2361-2369.
52. Zhao H, Janke M, Fournier P, Schirrmacher V: Recombinant Newcastle
disease virus expressing human interleukin-2 serves as a potential
candidate for tumor therapy. Virus Res 2008, 136:75-80.
53. Dafa’alla TH, Condon GC, Condon KC, Phillips CE, Morrison NI, Jin L,
Epton MJ, Fu G, Alphey L: Transposon-free insertions for insect genetic
engineering. Nat Biotechnol 2006, 24:820-821.
doi:10.1186/1472-6750-10-30
Cite this article as: Lynch et al.: Use of the piggyBac transposon to
create HIV-1 gag transgenic insect cell lines for continuous VLP
production. BMC Biotechnology 2010 10:30.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lynch et al. BMC Biotechnology 2010, 10:30
http://www.biomedcentral.com/1472-6750/10/30
Page 13 of 13